Please assess the completion status of the following clinical trial:

Trial Title: Ritalin: Antiasthenic Effect of Methylphenidate (Ritalin) in Palliative Care in Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced phase of neoplasm without any treatment available.~* Life expectancy of more than 1 month~* Karnofsky index more than 50%~* Chemotherapy IV or immunotherapy SC stopped more than 3 weeks before the end of the study~* Asthenia more than 5/10 on the visual analogical scale~* Informed consent form signed~* Affiliation to social security~Exclusion Criteria:~* Patients who can receive chemotherapy IV or immunotherapy SC in the month following the study~* Patients in whom disease can respond to chemotherapy~* Corticotherapy started less than 7 days before the study or potentially within the first week of the study~* Asthenia which can be easily corrected~* Contraindications to the amphetamines~* HADS score of anxiety and/or depression more than or egal to 17/21~* Potential surgery with general anesthesia in the first 7 days of the study~* Inability to quantify the sensation of asthenia on the visual analogical scale~* Pregnancy or feeding~* Guardianship

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): methylphenidate at 20mg per day during 7 days, at 20mg or 40mg per day during 7 days and 20, 40 or 60mg per day during 14 days
- 2 (Type: PLACEBO_COMPARATOR): placebo capsules

Based on this trial design, predict the completion outcome and termination type (if applicable).